# Sudipto Mukherjee

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 49 papers | 423 citations | 12 h-index | 19 g-index |
| 52 ext. papers | 638 ext. citations | 3.5 avg, IF | 3.23 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 49 | Choosing unwisely: Low-value care in older adults with a diagnosis of myelodysplastic syndrome.. *Journal of Clinical Oncology*, **2021**, 39, 1532-1532 | 2.2 | 0 |
| 48 | Analysis of distinct hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia. *Leukemia and Lymphoma*, **2021**, 62, 735-738 | 1.9 | 2 |
| 47 | Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia. *Transplantation and Cellular Therapy*, **2021**, 27, 917.e1-917.e9 | | 0 |
| 46 | Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes. *Journal of Clinical Oncology*, **2021**, 39, 3737-3746 | 2.2 | 14 |
| 45 | Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6 directed therapy. *Blood Advances*, **2021**, | 7.8 | 1 |
| 44 | A geno-clinical decision model for the diagnosis of myelodysplastic syndromes. *Blood Advances*, **2021**, 5, 4361-4369 | 7.8 | 2 |
| 43 | A case of hypereosinophilic syndrome with STAT5b N642H mutation. *Oxford Medical Case Reports*, **2021**, 2021, omaa129 | 0.6 | 1 |
| 42 | Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes. *Leukemia and Lymphoma*, **2020**, 61, 1943-1953 | 1.9 | 1 |
| 41 | Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS). *Blood*, **2020**, 136, 54-55 | 2.2 | |
| 40 | A Longitudinal Population Level Analysis of Healthcare Resource Utilization, Comorbidity, and Survival in Idiopathic Multicentric Castleman Disease Patients. *Blood*, **2020**, 136, 11-11 | 2.2 | |
| 39 | A Phase I/II Trial of CPX-351 + Palbociclib in Patients with Acute Myeloid Leukemia. *Blood*, **2020**, 136, 13-14 | 2.2 | 1 |
| 38 | A Personalized Clinical-Decision Tool to Improve the Diagnostic Accuracy of Myelodysplastic Syndromes. *Blood*, **2020**, 136, 33-35 | 2.2 | 2 |
| 37 | Genotype-Phenotype Correlations in Patients with Myeloid Malignancies Using Explainable Artificial Intelligence. *Blood*, **2020**, 136, 31-32 | 2.2 | 1 |
| 36 | Molecular dissection of normal karyotype acute myeloid leukemia.. *Journal of Clinical Oncology*, **2020**, 38, 7534-7534 | 2.2 | |
| 35 | Disparities in receipt of complete diagnostic evaluation to confirm myelodysplastic syndromes.. *Journal of Clinical Oncology*, **2020**, 38, 7555-7555 | 2.2 | |
| 34 | Genomics of therapy-related myeloid neoplasms. *Haematologica*, **2020**, 105, e98-e101 | 6.6 | 10 |
| 33 | Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. *American Journal of Hematology*, **2020**, 95, 1553-1561 | 7.1 | 9 |

| | | | |
|---|---|---|---|
| 32 | Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome. *Leukemia*, **2020**, 34, 957-962 | 10.7 | 16 |
| 31 | RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia. *Blood*, **2019**, 134, 2696-2696 | 2.2 | 1 |
| 30 | Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms. *Blood*, **2019**, 134, 4238-4238 | 2.2 | 2 |
| 29 | A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML) Using Artificial Intelligence. *Blood*, **2019**, 134, 2091-2091 | 2.2 | 8 |
| 28 | A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy. *Blood*, **2019**, 134, 2595-2595 | 2.2 | |
| 27 | Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. *Blood Advances*, **2019**, 3, 4228-4237 | 7.8 | 16 |
| 26 | Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes. *Nature Communications*, **2019**, 10, 5386 | 17.4 | 29 |
| 25 | Novel Therapies in Acute Myeloid Leukemia. *Seminars in Oncology Nursing*, **2019**, 35, 150955 | 3.7 | 6 |
| 24 | and mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes. *Leukemia and Lymphoma*, **2019**, 60, 1587-1590 | 1.9 | 9 |
| 23 | Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. *Blood Cancer Journal*, **2018**, 8, 4 | 7 | 21 |
| 22 | Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response. *Leukemia and Lymphoma*, **2018**, 59, 363-371 | 1.9 | 3 |
| 21 | Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series. *Clinical Lymphoma, Myeloma and Leukemia*, **2018**, 18, e463-e468 | 2 | 18 |
| 20 | Impact of Venous Thromboembolism during High Intensity Chemotherapy for Acute Leukemia Patients on Duration of Hospital Stay. *Blood*, **2018**, 132, 4806-4806 | 2.2 | 1 |
| 19 | Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia. *Blood*, **2018**, 132, 2075-2075 | 2.2 | |
| 18 | Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia. *Blood*, **2018**, 132, 1527-1527 | 2.2 | |
| 17 | Survival Outcomes of Patients with Therapy-Related Myelodysplastic Syndromes in the United States. *Blood*, **2018**, 132, 371-371 | 2.2 | |
| 16 | International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. *Blood*, **2018**, 132, 2115-2124 | 2.2 | 127 |
| 15 | The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail. *Oncologist*, **2017**, 22, 379-385 | 5.7 | 12 |

| | | | |
|---|---|---|---|
| 14 | A New Style of Transplantation May Gain Points When Treating Older Patients with Acute Myeloid Leukemia. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 715-716 | 4.7 | 0 |
| 13 | Therapy-related myelodysplastic syndromes, or are they?. *Blood Reviews*, **2017**, 31, 119-128 | 11.1 | 14 |
| 12 | Allogeneic Hematopoietic Cell Transplantation Is Safe and Effective Treatment in Patients with Myelodysplastic Syndromes Seventy Years and Older. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 1-2 | 4.7 | 1 |
| 11 | Accelerated Phase CML: Outcomes in Newly Diagnosed vs. Progression From Chronic Phase. *Current Hematologic Malignancy Reports*, **2016**, 11, 86-93 | 4.4 | 14 |
| 10 | Cost-effectiveness of treatments for high-risk myelodysplastic syndromes after failure of first-line hypomethylating agent therapy. *Expert Review of Pharmacoeconomics and Outcomes Research*, **2016**, 16, 275-84 | 2.2 | 4 |
| 9 | Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models. *Blood*, **2016**, 128, 216-216 | 2.2 | 16 |
| 8 | Is the cure the poison? The evolving story of therapy-related myeloid malignancies. *Leukemia and Lymphoma*, **2015**, 56, 839-40 | 1.9 | 1 |
| 7 | Impact of vancomycin-resistant enterococcal bacteremia on outcome during acute myeloid leukemia induction therapy. *Leukemia and Lymphoma*, **2015**, 56, 2536-42 | 1.9 | 12 |
| 6 | Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Associated With Poor Survival Outcomes in Myelodysplastic Syndromes. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, 489-95 | 2 | 4 |
| 5 | More is better: combination therapies for myelodysplastic syndromes. *Best Practice and Research in Clinical Haematology*, **2015**, 28, 22-31 | 4.2 | 17 |
| 4 | Allogeneic hematopoietic cell transplantation for myelodysplastic syndromes: lingering uncertainties and emerging possibilities. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 412-20 | 4.7 | 9 |
| 3 | APC mutations in myeloid malignancies: Incidence and impact on leukemogenesis.. *Journal of Clinical Oncology*, **2015**, 33, 11047-11047 | 2.2 | 1 |
| 2 | Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation. *Journal of the National Cancer Institute*, **2014**, 106, djt462 | 9.7 | 17 |
| 1 | Radiation Treatment for Localized Prostate Cancer and the Risk of Developing Myelodysplastic Syndromes (MDS). *Blood*, **2011**, 118, 120-120 | 2.2 | |